Detalhe da pesquisa
1.
Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Ann Surg Oncol
; 17(4): 1159-67, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20140529